| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Srihari Gopal, Gahan Pandina, Rosanne Lane, Isaac Nuamah, Bart Remmerie, Danielle Coppola, David Houg. A Post-hoc comparison of paliperidone palmitate to oral risperidone during initiation of long-acting risperidone injection in patients with acute schizophrenia. Innovations in clinical neuroscience. vol 8. issue 8. 2013-01-09. PMID:21922067. |
first-month data of a 13-week acute schizophrenia study were used to compare paliperidone palmitate to oral risperidone during initiation of long-acting injectable risperidone. |
2013-01-09 |
2023-08-12 |
Not clear |
| Sung-Wan Kim, Young-Chul Chung, Yo-Han Lee, Jeong-Hoon Lee, Seon-Young Kim, Kyung-Yeol Bae, Jae-Min Kim, Il-Seon Shin, Jin-Sang Yoo. Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial. International clinical psychopharmacology. vol 27. issue 5. 2013-01-09. PMID:22809972. |
paliperidone er versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial. |
2013-01-09 |
2023-08-12 |
Not clear |
| Sung-Wan Kim, Young-Chul Chung, Yo-Han Lee, Jeong-Hoon Lee, Seon-Young Kim, Kyung-Yeol Bae, Jae-Min Kim, Il-Seon Shin, Jin-Sang Yoo. Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial. International clinical psychopharmacology. vol 27. issue 5. 2013-01-09. PMID:22809972. |
this study aims to determine the effectiveness of paliperidone extended release (er) on cognitive function in patients with schizophrenia in comparison with risperidone. |
2013-01-09 |
2023-08-12 |
Not clear |
| Sung-Wan Kim, Young-Chul Chung, Yo-Han Lee, Jeong-Hoon Lee, Seon-Young Kim, Kyung-Yeol Bae, Jae-Min Kim, Il-Seon Shin, Jin-Sang Yoo. Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial. International clinical psychopharmacology. vol 27. issue 5. 2013-01-09. PMID:22809972. |
this was a 12-week, randomized, open-label study on schizophrenia patients who were receiving risperidone. |
2013-01-09 |
2023-08-12 |
Not clear |
| Mark Olfson, Tobias Gerhard, Cecilia Huang, Jeffrey A Lieberman, William V Bobo, Stephen Crysta. Comparative effectiveness of second-generation antipsychotic medications in early-onset schizophrenia. Schizophrenia bulletin. vol 38. issue 4. 2012-12-27. PMID:21307041. |
a 45-state medicaid claims file (2001-2005) was analyzed focusing on outpatients, aged 6-17 years, diagnosed with schizophrenia or a related disorder prior to starting a new episode of antipsychotic monotherapy with risperidone (n = 805), olanzapine (n = 382), quetiapine (n = 260), aripiprazole (n = 173), or ziprasidone (n = 125). |
2012-12-27 |
2023-08-12 |
Not clear |
| Peter J Weiden, Nina R Schooler, Jeremy C Weedon, Abdel Elmouchtari, Ayako Sunakawa-McMilla. Maintenance treatment with long-acting injectable risperidone in first-episode schizophrenia: a randomized effectiveness study. The Journal of clinical psychiatry. vol 73. issue 9. 2012-12-26. PMID:22938760. |
maintenance treatment with long-acting injectable risperidone in first-episode schizophrenia: a randomized effectiveness study. |
2012-12-26 |
2023-08-12 |
Not clear |
| Pierre Chue, James Chu. The cost-effectiveness of risperidone long-acting injection in the treatment of schizophrenia. Expert review of pharmacoeconomics & outcomes research. vol 12. issue 3. 2012-12-10. PMID:22812548. |
the cost-effectiveness of risperidone long-acting injection in the treatment of schizophrenia. |
2012-12-10 |
2023-08-12 |
human |
| Eesha Sharma, Naren P Rao, Ganesan Venkatasubramanian, Rishikesh V Behere, Shivarama Varambally, Bangalore N Gangadha. Successful treatment of co-morbid schizophrenia and multiple sclerosis. Asian journal of psychiatry. vol 3. issue 4. 2012-12-10. PMID:23050895. |
we, for the first time, report a patient with ms and paranoid schizophrenia successfully treated with concurrent use of clozapine and risperidone with interferon-beta-1a. |
2012-12-10 |
2023-08-12 |
Not clear |
| H R Vinay, G S Keerthi Sundar, Rishikesh V Behere, Rashmi Arasappa, Naren P Rao, Ganesan Venkatasubramanian, P T Sivakumar, B N Gangadha. Effect of risperidone on metabolic parameters in antipsychotic-naïve schizophrenia: A prospective one year follow-up study. Asian journal of psychiatry. vol 4. issue 1. 2012-12-10. PMID:23050920. |
effect of risperidone on metabolic parameters in antipsychotic-naïve schizophrenia: a prospective one year follow-up study. |
2012-12-10 |
2023-08-12 |
Not clear |
| Hua-Lin Cai, Huan-De Li, Xian-Zhong Yan, Bo Sun, Qi Zhang, Miao Yan, Wen-Yuan Zhang, Pei Jiang, Rong-Hua Zhu, Yi-Ping Liu, Ping-Fei Fang, Ping Xu, Hai-Yan Yuan, Xiang-Hui Zhang, Li Hu, Wen Yang, Hai-Sen Y. Metabolomic analysis of biochemical changes in the plasma and urine of first-episode neuroleptic-naïve schizophrenia patients after treatment with risperidone. Journal of proteome research. vol 11. issue 8. 2012-12-05. PMID:22800120. |
metabolomic analysis of biochemical changes in the plasma and urine of first-episode neuroleptic-naïve schizophrenia patients after treatment with risperidone. |
2012-12-05 |
2023-08-12 |
Not clear |
| Hua-Lin Cai, Huan-De Li, Xian-Zhong Yan, Bo Sun, Qi Zhang, Miao Yan, Wen-Yuan Zhang, Pei Jiang, Rong-Hua Zhu, Yi-Ping Liu, Ping-Fei Fang, Ping Xu, Hai-Yan Yuan, Xiang-Hui Zhang, Li Hu, Wen Yang, Hai-Sen Y. Metabolomic analysis of biochemical changes in the plasma and urine of first-episode neuroleptic-naïve schizophrenia patients after treatment with risperidone. Journal of proteome research. vol 11. issue 8. 2012-12-05. PMID:22800120. |
using a targeted tandem mass spectrometry (ms/ms)-based metabolomic platform, we compared metabolic signatures consisting of monoamine and amino acid neurotransmitter (nt) metabolites in plasma/urine simultaneously between first-episode neuroleptic-naïve schizophrenia patients (fenns) and healthy controls before and after a 6-week risperidone monotherapy, which suggest that the patient nt profiles are restoring during treatment. |
2012-12-05 |
2023-08-12 |
Not clear |
| Hua-Lin Cai, Huan-De Li, Xian-Zhong Yan, Bo Sun, Qi Zhang, Miao Yan, Wen-Yuan Zhang, Pei Jiang, Rong-Hua Zhu, Yi-Ping Liu, Ping-Fei Fang, Ping Xu, Hai-Yan Yuan, Xiang-Hui Zhang, Li Hu, Wen Yang, Hai-Sen Y. Metabolomic analysis of biochemical changes in the plasma and urine of first-episode neuroleptic-naïve schizophrenia patients after treatment with risperidone. Journal of proteome research. vol 11. issue 8. 2012-12-05. PMID:22800120. |
to detect and identify potential biomarkers associated with schizophrenia and risperidone treatment, we also performed a combined ultraperformance liquid chromatography-mass spectrometry (uplc-ms) and 1h nuclear magnetic resonance (nmr)-based metabolomic profiling of the same samples, indicating a further deviation of the patients' global metabolic profile from that of controls. |
2012-12-05 |
2023-08-12 |
Not clear |
| Zoja Babinkostova, Branislav Stefanovsk. Forms of antipsychotic therapy: improved individual outcomes under personalised treatment of schizophrenia focused on depression. The EPMA journal. vol 2. issue 4. 2012-12-04. PMID:23199176. |
most of the studies referred that clozapine, olanzapine, quetiapine and risperidone have an antidepressant spectrum of activity in patients with schizophrenia. |
2012-12-04 |
2023-08-12 |
Not clear |
| Eric J de Waal, Wendy Roosen, Petra Vinken, John Vandenberghe, Patrick Sterkens, Lieve Lammen. Mechanistic investigations on the etiology of Risperdal(®) Consta(®)-induced bone changes in female Wistar Hannover rats. Toxicology. vol 299. issue 2-3. 2012-11-21. PMID:22595365. |
risperdal(®) consta(®) is a long-acting, intramuscular formulation of risperidone microspheres for the biweekly treatment of schizophrenia and other psychiatric disorders. |
2012-11-21 |
2023-08-12 |
human |
| Saeko Ikai, Gary Remington, Takefumi Suzuki, Hiroyoshi Takeuchi, Takashi Tsuboi, Ryosuke Den, Jinichi Hirano, Kenichi Tsunoda, Masahiko Nishimoto, Koichiro Watanabe, Masaru Mimura, David Mamo, Hiroyuki Uchid. A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia. The Journal of clinical psychiatry. vol 73. issue 8. 2012-11-13. PMID:22967779. |
a cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: implications for dopamine d2 receptor occupancy during maintenance treatment in schizophrenia. |
2012-11-13 |
2023-08-12 |
Not clear |
| Yuya Mizuno, Robert R Bies, Gary Remington, David C Mamo, Takefumi Suzuki, Bruce G Pollock, Takashi Tsuboi, Koichiro Watanabe, Masaru Mimura, Hiroyuki Uchid. Dopamine D2 receptor occupancy with risperidone or olanzapine during maintenance treatment of schizophrenia: a cross-sectional study. Progress in neuro-psychopharmacology & biological psychiatry. vol 37. issue 1. 2012-11-08. PMID:22230651. |
dopamine d2 receptor occupancy with risperidone or olanzapine during maintenance treatment of schizophrenia: a cross-sectional study. |
2012-11-08 |
2023-08-12 |
human |
| Yuya Mizuno, Robert R Bies, Gary Remington, David C Mamo, Takefumi Suzuki, Bruce G Pollock, Takashi Tsuboi, Koichiro Watanabe, Masaru Mimura, Hiroyuki Uchid. Dopamine D2 receptor occupancy with risperidone or olanzapine during maintenance treatment of schizophrenia: a cross-sectional study. Progress in neuro-psychopharmacology & biological psychiatry. vol 37. issue 1. 2012-11-08. PMID:22230651. |
in this study, daily peak and trough d2 receptor occupancy levels were estimated in clinically stable patients with schizophrenia (dsm-iv) who were receiving risperidone or olanzapine. |
2012-11-08 |
2023-08-12 |
human |
| Yuya Mizuno, Robert R Bies, Gary Remington, David C Mamo, Takefumi Suzuki, Bruce G Pollock, Takashi Tsuboi, Koichiro Watanabe, Masaru Mimura, Hiroyuki Uchid. Dopamine D2 receptor occupancy with risperidone or olanzapine during maintenance treatment of schizophrenia: a cross-sectional study. Progress in neuro-psychopharmacology & biological psychiatry. vol 37. issue 1. 2012-11-08. PMID:22230651. |
35 subjects with stable schizophrenia completed the study (mean±sd age, 48.8±13.8years; male [n=14]; asians [n=23], caucasians [n=12]; risperidone [n=20] at 3.2±2.3mg/day, and olanzapine [n=15] at 9.2±4.9mg/day) between september and december 2010. |
2012-11-08 |
2023-08-12 |
human |
| Gahan Pandina, Stuart Kushner, Keith Karcher, Magali Haa. An open-label, multicenter evaluation of the long-term safety and efficacy of risperidone in adolescents with schizophrenia. Child and adolescent psychiatry and mental health. vol 6. issue 1. 2012-11-07. PMID:22676070. |
an open-label, multicenter evaluation of the long-term safety and efficacy of risperidone in adolescents with schizophrenia. |
2012-11-07 |
2023-08-12 |
Not clear |
| Gahan Pandina, Stuart Kushner, Keith Karcher, Magali Haa. An open-label, multicenter evaluation of the long-term safety and efficacy of risperidone in adolescents with schizophrenia. Child and adolescent psychiatry and mental health. vol 6. issue 1. 2012-11-07. PMID:22676070. |
data on the long-term efficacy, safety, and tolerability of risperidone in adolescents with schizophrenia are limited. |
2012-11-07 |
2023-08-12 |
Not clear |